Monitor upcoming FDA End-of-Phase 2 meeting for VCN-01 in pancreatic cancer and track achievement of milestones from the SYN-020 licensing deal. The going concern qualification warrants attention to future financing needs despite current cash runway into Q1 2027.
Price Chart
Executive Summary
Theriva Biologics reported financial results for 2025 and provided corporate updates, including licensing SYN-020 to Rasayana Therapeutics for up to $38 million in potential milestones, advancing VCN-01 toward pivotal trials in pancreatic cancer and retinoblastoma, and maintaining a cash runway into Q1 2027. The company incurred a net loss of $23.7 million in 2025, driven by a $9 million contingent consideration adjustment.
Key Financial Metrics
Key Facts
- Licensed SYN-020 to Rasayana Therapeutics for up to $38 million in potential milestones plus royalties
- Received $300,000 upfront payment from Rasayana with potential for $16M in development milestones and $22M in sales milestones
- Cash and cash equivalents were $13.1 million as of December 31, 2025, with $15.2 million as of February 26, 2026
- Net loss of $23.7 million for 2025, compared to $25.7 million in 2024
- General and administrative expenses increased 109% to $15.4 million due to a $9 million contingent consideration adjustment
- Research and development expenses decreased 28% to $8.6 million
- Received positive scientific advice from EMA on Phase 3 trial design for VCN-01 in pancreatic cancer
- Audited financial statements include a going concern qualification
Financial Impact
Net loss of $23.7 million in 2025 with $9 million contingent consideration adjustment; $300,000 upfront payment from SYN-020 licensing with potential for up to $38 million in total milestones
Risk Factors
- Going concern qualification in audited financial statements indicates substantial doubt about the company's ability to continue operations
- High dependence on successful development of VCN-01, which is still in clinical trials
- Future capital requirements may necessitate additional funding rounds
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-026765 |
| Document: tm268491d1_8k.htm | 0001104659-26-026765 |
| Document: 0001104659-26-026765-index-headers.html | 0001104659-26-026765 |
| Document: 0001104659-26-026765-index.html | 0001104659-26-026765 |
| Document: 0001104659-26-026765.txt | 0001104659-26-026765 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $0.2300 $0.2490 | ▲ +8.26% | ▲ +9.32% | $0.2306 (+0.26%) |
Aug 11, 2026 7w ago | Press Release | $0.2300 $0.2490 | ▲ +8.26% | ▲ +9.32% | $0.2306 (+0.26%) |
Aug 4, 2026 8w ago | 8-K | $0.2300 $0.2490 | ▼ −8.26% | ▼ −9.50% | $0.2306 (−0.26%) |
Jul 7, 2026 12w ago | 8-K | $0.2354 $0.2227 | ▼ −5.40% | ▼ −6.73% | $0.2306 (−2.04%) |
Jun 11, 2026 16w ago | Press Release | $0.3070 $0.2345 | ▼ −23.62% | ▼ −25.51% | $0.2306 (−24.89%) |
Apr 17, 2026 23w ago | 8-K | $0.4100 $0.3000 | ▼ −26.83% | ▼ −31.03% | $0.2306 (−43.76%) |
Mar 12, 2026 29w ago | 8-K | $0.1800 $0.2300 | ▲ +27.78% | ▲ +25.80% | $0.2306 (+28.11%) |
Mar 12, 2026 29w ago | Press Release | $0.1800 $0.2300 | ▲ +27.78% | ▲ +25.80% | $0.2306 (+28.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access